

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau



(43) International Publication Date
22 April 2004 (22.04.2004)

PCT

(10) International Publication Number
WO 2004/032614 A2

(51) International Patent Classification⁷: **A01K 67/027**

(21) International Application Number:
PCT/EP2003/010118

(22) International Filing Date:
11 September 2003 (11.09.2003)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
60/410,776 13 September 2002 (13.09.2002) US
60/426,609 15 November 2002 (15.11.2002) US
60/444,920 4 February 2003 (04.02.2003) US

(71) Applicant (for all designated States except US): **INGENIUM PHARMACEUTICALS AG** [DE/DE];
Fraunhofer Strasse 13, 82152 Martinsried (DE).

(72) Inventors; and

(75) Inventors/Applicants (for US only): **KLOCKE, Rainer** [DE/DE]; Grosshaderner Strasse 5b, 82152 Martinsried (DE). **MARQUARDT, Andreas** [DE/DE]; Fraunhofer Strasse 13, 82152 Martinsried (DE). **PERAUS, Gisela** [DE/DE]; Fraunhofer Strasse 13, 82152 Martinsried (DE). **STUMM, Gabriele** [DE/DE]; Fraunhofer Strasse 13, 82152 Martinsried (DE). **WABNITZ, Philipp** [DE/DE]; Fraunhofer Strasse 13, 82152 Martinsried (DE).

(74) Agent: **DÖRRIES, FRANK-MOLNIA & POHLMAN**;
Triftstrasse 13, 80538 München (DE).

(81) Designated States (national): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE,

GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.

(84) Designated States (regional): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Declaration under Rule 4.17:

— as to the identity of the inventor (Rule 4.17(i)) for the following designations AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VC, VN, YU, ZA, ZM, ZW, ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG)

Published:

— without international search report and to be republished upon receipt of that report

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: CYTOPLASMIC DYNEIN HEAVY CHAIN 1 GENES, EXPRESSION PRODUCTS, NON-HUMAN ANIMAL MODEL: USES IN HUMAN NEUROLOGICAL DISEASES

(57) Abstract: A non-human animal model is provided, particularly a mouse model for movement hyperactivity, excitotoxicity disorders (e.g. myoclonic cramping) and neurodegeneration, in which modified cytoplasmic dynein heavy chain 1 is expressed. Modified human and mouse cytoplasmic dynein heavy chain 1 proteins and nucleic acids are also provided, including the corresponding recombinant proteins. The invention further provides uses for the non-human animal model and the modified cytoplasmic dynein heavy chain 1 proteins and nucleic acids, in particular for the diagnosis and treatment of medical conditions associated with over-expression of cytoplasmic dynein heavy chain 1.

WO 2004/032614 A2